Abstract
Abstract: :
Purpose:To evaluate the effect of the association of bimatoprost to latanoprost on intraocular pressure in primary open–angle glaucoma. Methods:A twelve–week open–label randomized clinical trial was conducted including sixteen patients (32 eyes) with primary open–angle glaucoma. In the first 4 weeks, latanoprost 0.005% was prescribed for both eyes of the participants, any other ocular hypotensive drug was discontinued and the intraocular pressure at the end of this period was considered the baseline value. After that period, the participants were conducted to the phase 1 (4 weeks duration), in which bimatoprost 0.03% was associated to latanoprost in one randomly assigned eye (case group) of each patient, and only latanoprost was instilled in the fellow eye (control group). In the phase 2 (4 weeks duration), bimatoprost was discontinued from the case group, and in the control group, bimatoprost was substituted for latanoprost. The intraocular pressure was measured weekly in the phases 1 and 2. Results:At the end of the phase 1, there was a mean increase in intraocular pressure of 1.7 mmHg (95% Confidence Interval: 0.1 – 3.3 ; p=0.030) on the case group (bimatoprost+latanoprost) which returned to baseline values after discontinuation of bimatoprost (phase 2). There was no statistically significant alteration in intraocular pressure of the control group in both phases. Conclusions:The adjunctive use of bimatoprost and latanoprost in patients with primary open–angle glaucoma causes an increase in the intraocular pressure. The association of these two drugs is not recommended for treatment of primary open–angle glaucoma.
Keywords: intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • drug toxicity/drug effects